Alterity Therapeutics Limited
ATHE•NASDAQ•Healthcare•Biotechnology

About Alterity Therapeutics

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer’s disease, Huntington disease, Parkinson’s disease, and other neurological disorders in Australia. The company’s lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase I clinical trial for the treatment of Parkinson’s disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; and ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy, as well as biomarkers of progression in multiple system atrophy. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is based in Melbourne, Australia.

Company Information

SectorHealthcare
IndustryBiotechnology
CEODavid Stamler
Founded1997
Employees9
CountryAustralia
Fiscal YearJuly - June

Stock Details

ExchangeNASDAQ (NASDAQ)
CurrencyAUD - AUD
TypeStock

Contact Information

Websitealteritytherapeutics.com
Phone61 3 9349 4906
Address
350 Collins Street, Suite 4 Melbourne, VIC 3000 Australia

Corporate Identifiers

CIK0001131343
CUSIP02155X106
ISINUS02155X2053
SIC2834

Leadership Team & Key Executives

Dr. David A. Stamler M.D.
Chief Executive Officer and Director
Abby Macnish Niven B.Com., B.Sc., C.F.A.
Chief Financial Officer and Company Secretary
Dr. Rudolph Emile Tanzi Ph.D.
Chief Scientific Advisor and Member of Research and Development Advisory Board
Dr. Steven D. Targum M.D.
Chief Medical Advisor
Dr. Robert Cherny
Head of Research